Biotest AG VZ Stock
Price
Target price
€29.20
€29.20
-0.340%
-0.1
-0.340%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Biotest
sharewise wants to provide you with the best news and tools for Biotest, so we directly link to the best financial data sources.
Financials
News
EQS-News: Biotest AG opens 12th plasma collection centre in Germany
EQS-News: Biotest AG opens 12th plasma collection centre in Germany
EQS-News: Biotest AG increased sales by 32% in the financial year 2023
EQS-News: Biotest AG increased sales by 32% in the financial year 2023
EQS-News: Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
EQS-News: Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
EQS-News: Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
EQS-News: Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
EQS-News: Biotest AG opens 11th plasma collection centre in Germany
EQS-News: Biotest AG opens 11th plasma collection centre in Germany
EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
EQS-News: Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation